{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:35:23Z","timestamp":1785404123242,"version":"3.56.0"},"posted":{"date-parts":[[2025,9,25]]},"group-title":"Animal Behavior and Cognition","reference-count":33,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"funder":[{"award":["UG3DA050322"],"award-info":[{"award-number":["UG3DA050322"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Rates of opioid use disorder (OUD) and overdose deaths have increased dramatically in recent years. Currently approved medications for OUD include the opioid agonists methadone and buprenorphine, and the opioid antagonist naltrexone. However, relapse rates are high due to an impaired ability for addicts to control their urge to consume due to strong cravings, and the extreme severity of withdrawal symptoms. Additionally, the nature of the agonists can lead to abuse of those compounds as well. Non-opioid targets, such as glutamate receptors, are potentially ideal for developing intervention strategies with the goal of reducing OUD, relapse, and overdose death. NYX-783 is a small molecule positive allosteric modulator for the glutamate receptor NMDA. It has been shown to modulate learning and memory, both of which are impaired in drug addicts, and known play a role in relapse. Using mice, we have conducted preclinical studies to evaluate the potential for NYX-783 as a therapeutic for OUD with assessment of several outcomes: 1) respiratory depression, 2) consumption during maintenance of regular consumption as well as post-abstinence reinstatement, 3) motivation for consumption, 4) somatic withdrawals, and 5) the development of aversion to withdrawal symptoms. For respiratory depression studies, mice were pretreated 1h prior with NYX-783 and respiratory rates were monitored for 15min after each escalating dose of oxycodone. No effects were seen for any dose of NYX-783. To test for effects on drug consumption, mice were trained to orally self-administer oxycodone and then treated every two days with different doses of NYX-783 or entering an abstinence phase prior to testing with NYX-783. No effect on intake at clinically-relevant doses was observed during regular maintenance or post-abstinence intake. Additionally, we used a progressive ratio to assess the motivation self-administering mice had for reward acquisition, and no effect of NYX-783 was observed on rewards earned. We next evaluated withdrawal using two separate paradigms to test for effects of NYX-783 on, 1) for somatic withdrawal symptoms, 2) aversion to the state of withdrawal. For somatic withdrawal, using higher doses of naloxone (1 mg\/kg), NYX-783 did not attenuate jumping behavior. For aversion to withdrawal, three aversion pairings were completed that consisted of oxycodone treatment, followed by NYX-783 preceding a low dose of naloxone (0.1mg\/kg ip) immediately before pairing in a specific context. These alternated with neutral (saline) pairings daily. We observed a significant improvement in aversion scores in female mice treated with NYX-783, and a trending significant improvement in males. This suggests a potential therapeutic use for NYX-783 in reducing the negative state of withdrawal that can drive relapse in OUD.<\/jats:p>","DOI":"10.1101\/2025.09.25.678598","type":"posted-content","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T03:35:12Z","timestamp":1758857712000},"source":"Crossref","is-referenced-by-count":0,"title":["The NMDAR positive allosteric modulator NYX-783 selectively blocks opioid withdrawal conditioned place aversion in mice"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9424-7191","authenticated-orcid":false,"given":"Joseph R.","family":"Trinko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3365-7634","authenticated-orcid":false,"given":"Ethan","family":"Foscue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deven M.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1922-1201","authenticated-orcid":false,"given":"Summer L.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8970-8483","authenticated-orcid":false,"given":"Robert T.","family":"Malison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3012-4349","authenticated-orcid":false,"given":"Rajita","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5831-8595","authenticated-orcid":false,"given":"Jane R.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4770-2590","authenticated-orcid":false,"given":"Ralph J.","family":"DiLeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025092910401385000_2025.09.25.678598v1.1","unstructured":"2023 National Survey on Drug Use and Health (NSDUH) Releases | CBHSQ Data. https:\/\/www.samhsa.gov\/data\/data-we-collect\/nsduh-national-survey-drug-use-and-health\/national-releases\/2023."},{"key":"2025092910401385000_2025.09.25.678598v1.2","doi-asserted-by":"publisher","DOI":"10.15620\/cdc\/170565"},{"key":"2025092910401385000_2025.09.25.678598v1.3","first-page":"416","article-title":"Opioid Use Disorder: Medical Treatment Options","volume":"100","year":"2019","journal-title":"afp"},{"key":"2025092910401385000_2025.09.25.678598v1.4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1360-0443.2003.00334.x","article-title":"Short-term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users","volume":"98","year":"2003","journal-title":"Addiction"},{"key":"2025092910401385000_2025.09.25.678598v1.5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jsat.2014.07.009","article-title":"The multi-site Prescription Opioid Addiction Treatment Study: 18-month outcomes","volume":"48","year":"2015","journal-title":"J Subst Abuse Treat"},{"key":"2025092910401385000_2025.09.25.678598v1.6","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.258004"},{"key":"2025092910401385000_2025.09.25.678598v1.7","doi-asserted-by":"crossref","first-page":"109666","DOI":"10.1016\/j.neuropharm.2023.109666","article-title":"ADX106772, an mGlu2 receptor positive allosteric modulator, selectively attenuates oxycodone taking and seeking","volume":"238","year":"2023","journal-title":"Neuropharmacology"},{"key":"2025092910401385000_2025.09.25.678598v1.8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/jnc.15706","article-title":"\u03b12\u03b4-1 protein drives opioid-induced conditioned reward and synaptic NMDA receptor hyperactivity in the nucleus accumbens","volume":"164","year":"2023","journal-title":"Journal of Neurochemistry"},{"key":"2025092910401385000_2025.09.25.678598v1.9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11916-018-0674-8","article-title":"Novel Pharmacological Nonopioid Therapies in Chronic Pain","volume":"22","year":"2018","journal-title":"Curr Pain Headache Rep"},{"key":"2025092910401385000_2025.09.25.678598v1.10","doi-asserted-by":"crossref","first-page":"1552084","DOI":"10.3389\/fpsyt.2025.1552084","article-title":"Ketamine in treating opioid use disorder and opioid withdrawal: a scoping review","volume":"16","year":"2025","journal-title":"Front Psychiatry"},{"key":"2025092910401385000_2025.09.25.678598v1.11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1253736"},{"key":"2025092910401385000_2025.09.25.678598v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2009.04.012"},{"key":"2025092910401385000_2025.09.25.678598v1.13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/ijnp\/pyx096","article-title":"NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-\u03b2-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory","volume":"21","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"2025092910401385000_2025.09.25.678598v1.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01614-3"},{"key":"2025092910401385000_2025.09.25.678598v1.15","doi-asserted-by":"crossref","first-page":"173485","DOI":"10.1016\/j.pbb.2022.173485","article-title":"Rapastinel accelerates loss of withdrawal signs after repeated morphine and blunts relapse to conditioned place preference","volume":"221","year":"2022","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"2025092910401385000_2025.09.25.678598v1.16","doi-asserted-by":"crossref","first-page":"e0184876","DOI":"10.1371\/journal.pone.0184876","article-title":"Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse","volume":"12","year":"2017","journal-title":"PLoS One"},{"key":"2025092910401385000_2025.09.25.678598v1.17","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1038\/s41598-023-33458-8","article-title":"Ketogenic diet enhances the effects of oxycodone in mice","volume":"13","year":"2023","journal-title":"Sci Rep"},{"key":"2025092910401385000_2025.09.25.678598v1.18","doi-asserted-by":"publisher","DOI":"10.1126\/science.134.3483.943"},{"key":"2025092910401385000_2025.09.25.678598v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0270(95)00153-0"},{"key":"2025092910401385000_2025.09.25.678598v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(02)00458-X"},{"key":"2025092910401385000_2025.09.25.678598v1.21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0091-3057(81)90320-8","article-title":"Opiate dependence following acute injections of morphine and naloxone: the assessment of various withdrawal signs","volume":"14","year":"1981","journal-title":"Pharmacol Biochem Behav"},{"key":"2025092910401385000_2025.09.25.678598v1.22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lfs.2017.07.016","article-title":"Long-term morphine delivery via slow release morphine pellets or osmotic pumps: Plasma concentration, analgesia, and naloxone-precipitated withdrawal","volume":"185","year":"2017","journal-title":"Life Sci"},{"key":"2025092910401385000_2025.09.25.678598v1.23","doi-asserted-by":"publisher","DOI":"10.1007\/s002139900358"},{"key":"2025092910401385000_2025.09.25.678598v1.24","doi-asserted-by":"crossref","first-page":"208931","DOI":"10.1016\/j.josat.2022.208931","article-title":"Using ecological momentary assessments of negative affect and craving during residential opioid use disorder treatment to predict patients\u2019 relapse to substance use","volume":"146","year":"2023","journal-title":"J Subst Use Addict Treat"},{"key":"2025092910401385000_2025.09.25.678598v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPSYCH.2019.05.023"},{"key":"2025092910401385000_2025.09.25.678598v1.26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41398-024-03159-5","article-title":"Re-evaluating our focus in addiction: emotional dysregulation is a critical driver of relapse to drug use","volume":"14","year":"2024","journal-title":"Transl Psychiatry"},{"key":"2025092910401385000_2025.09.25.678598v1.27","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf0364"},{"key":"2025092910401385000_2025.09.25.678598v1.28","doi-asserted-by":"crossref","first-page":"8460","DOI":"10.1038\/s41598-023-35673-9","article-title":"Sex differences in VTA GABA transmission and plasticity during opioid withdrawal","volume":"13","year":"2023","journal-title":"Sci Rep"},{"key":"2025092910401385000_2025.09.25.678598v1.29","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0595-22.2022"},{"key":"2025092910401385000_2025.09.25.678598v1.30","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011163"},{"key":"2025092910401385000_2025.09.25.678598v1.31","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12400"},{"key":"2025092910401385000_2025.09.25.678598v1.32","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3181c38c25"},{"key":"2025092910401385000_2025.09.25.678598v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2016.07.006"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.09.25.678598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:40:12Z","timestamp":1768470012000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.09.25.678598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":33,"URL":"https:\/\/doi.org\/10.1101\/2025.09.25.678598","relation":{},"subject":[],"published":{"date-parts":[[2025,9,25]]},"subtype":"preprint"}}